Trial shows no clear benefit from cannabis for patients with MS
نویسندگان
چکیده
منابع مشابه
Clear view, clear benefit.
n this issue of the Journal, a clinical investigation by Ozaki et al focuses on the flushing solution used for image acquisition with frequency-domain optical coherence tomography (FD-OCT).1 The authors present the cross-sectional area measurement as a quantitative evaluation using low-molecular dextran L (LMD-L) approximate to that of contrast media, and the non-inferiority of LMD-L to contras...
متن کاملPrimary Clear Cell Carcinoma with no Diethylstilbestrol Exposure; Case Series
One of the rare neoplasms of cervix uteri and vagina is clear cell carcinoma; mostly in patients with a positive past medical history of intrauterine diethylstilbestrol (DES) exposure which reveals the importance of other unknown risk factors of gynecologic neoplasms. 2 Asian women referred to the gynecology-oncology department. The first one came with a complaint of prolonged vaginal discharge...
متن کاملMedical cannabis: time for clear thinking.
The debate about the medical use of cannabis in Australia has become confused with the proposal for a formal clinical trial instead of proceeding to legislation in New South Wales, the Australian Capital Territory and Victoria. Debates about prohibition of cannabis have a long history,1 as has the proposal for medical cannabis in Australia.2 Politicians are nervous about being “soft on drugs”, ...
متن کاملWhen marketing and science intersect: do patients with MS benefit?
MS entered the treatment era a scant 9 years ago with US Food and Drug Administration (FDA) approval of interferon -1b. Since then, two interferon -1a preparations, an amino acid polymer, glatiramer acetate; and a chemotherapeutic agent, mitoxantrone, have received regulatory approval in the United States and many other countries for various forms of relapsing MS. Approval is based on modest bu...
متن کاملNo added benefit from nebulized amiloride in patients with cystic fibrosis.
In cystic fibrosis (CF) airway epithelial sodium absorption is increased 2-3 fold. Since sodium absorption is inhibited by the sodium channel blocker amiloride, our aim was to assess its therapeutic benefit in cystic fibrosis. A randomized, double-blind, placebo-controlled, cross-over trial of nebulized amiloride was performed in 23 patients with cystic fibrosis. Amiloride or placebo was admini...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 2003
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.327.7424.1128